小剂量地西他滨联合阿柔比星+阿糖胞苷+重组粒细胞集落刺激因子方案治疗骨髓增生异常综合征的效果分析

Effect analysis of low-dose Decitabine combined Arubicin+Cytarabine+Recombinant Granulocyte Colony Stimulating Factor programme in the treatment of myelodysplastic syndrome

目的探讨分析小剂量地西他滨联合阿柔比星+阿糖胞苷+重组粒细胞集落刺激因子(CAG)方案治疗骨髓增生异常综合征的效果。方法选取2011年10月~2018年10月我院收治的82例骨髓增生异常综合征患者作为研究对象,按随机数字表法分成研究组(n=41)和参照组(n=41)。参照组患者予以常规CAG方案治疗,研究组患者则采用小剂量地西他滨联合CAG方案进行治疗。比较两组患者的临床治疗效果,观察两组治疗后的不良反应发生情况。结果研究组患者的治疗缓解率为78.05%,高于参照组的58.54%,差异有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论骨髓增生异常综合征患者应用小剂量地西他滨联合CAG方案治疗,有助于提升患者的临床缓解率,且不会明显增加不良反应,安全性良好。

Objective To investigate and analyze the efficacy of low-dose Decitabine combined with Arubicin+Cytarabine+Recombinant Granulocyte Colony Stimulating Factor(CAG)regimen in the treatment of myelodysplastic syndrome.Methods From October 2011 to October 2018,82 patients with myelodysplastic syndrome admitted to our hospital were selected as study subjects.They were divided into the study group(n=41)and the reference group(n=41)by the random number table method.Patients in the reference group were given conventional CAG,patients in the study group were treated with low-dose Decitabine combined CAG regimen.The clinical treatment effect of the two groups of patients was compared,and the adverse reactions of the two groups after treatment were observed.Results The remission rate of the patients in the study group was 78.05%,which was higher than that in the control group(58.54%),the difference was statistically significant(P<0.05).There was no significant difference in the total incidence rate of adverse reaction between the two groups(P>0.05).Conclusion The treatment of patients with myelodysplastic syndrome with low-dose Decitabine combined with CAG is helpful to improve the clinical remission rate,and will not increase the obvious adverse reactions,and the safety is good.